Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015', provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6 Therapeutics Development 7 Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 7 Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 8 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 9 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 12 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 13 Human Stem Cells Institute 13 Juventas Therapeutics, Inc. 14 Lacer, S.A. 15 Nuo Therapeutics, Inc. 16 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 ALD-201 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Biglycan Therapy for Cardiovascular Diseases - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Cryocell - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 JVS-100 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LA-419 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 34 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7 Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2015 13 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H1 2015 14 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H1 2015 15 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H1 2015 16 Assessment by Monotherapy Products, H1 2015 17 Number of Products by Stage and Target, H1 2015 19 Number of Products by Stage and Mechanism of Action, H1 2015 21 Number of Products by Stage and Route of Administration, H1 2015 23 Number of Products by Stage and Molecule Type, H1 2015 25 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2015 34 Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2015 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.